Table 3 Comparison of correlation of risk results for spike IgG and PsV-nAb ID50 across three randomized, placebo-controlled COVID-19 vaccine efficacy trials (U.S. study sites)
From: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Vaccine Platforma | Trial | Ab Marker at 2 or 4 Wksb Post-Vaccination | Follow-Up Post Vaccination | Estimated Hazard Ratio per 10-fold Increase in the Marker (95% CI) | P Value | Q Value | FWER-Adjusted P Value |
|---|---|---|---|---|---|---|---|
mRNA | COVE | Spike IgG | 126 days | 0.66 (0.50, 0.88) | 0.005 | 0.014 | 0.010 |
Ad26 | ENSEMBLE-U.S. | Spike IgG | 83 days | 0.62 (0.28, 1.37) | 0.24 | 0.35 | 0.36 |
Recombinant Protein | PREVENT-19 | Spike IgG | 73 days | 0.36 (0.20, 0.64) | <0.001 | 0.005 | 0.005 |
mRNA | COVE | RBD IgG | 126 days | 0.57 (0.40, 0.82) | 0.002 | 0.008 | 0.008 |
Ad26 | ENSEMBLE-U.S. | RBD IgG | 83 days | 0.50 (0.21, 1.21) | 0.13 | 0.24 | 0.22 |
Recombinant Protein | PREVENT-19 | RBD IgG | 73 days | 0.35 (0.18, 0.69) | 0.002 | 0.012 | 0.013 |
mRNA | COVE | PsV-nAb ID50 | 126 days | 0.42 (0.27, 0.65) | <0.001 | 0.002 | 0.003 |
Ad26 | ENSEMBLE-U.S. | PsV-nAb ID50 | 83 days | 0.38 (0.13, 1.12) | 0.078 | 0.22 | 0.20 |
Recombinant Protein | PREVENT-19 | PsV-nAb ID50 | 73 days | 0.39 (0.19, 0.82) | 0.013 | 0.032 | 0.030 |
